While Vertex’s drug pricing battle with British regulators continues, it has made advances abroad, signing a deal this week to make two of its cystic fibrosis drugs available in Scotland. 

All three of Vertex’s drugs for the genetic lung disorder cystic fibrosis have been approved for use in Europe. But the company (Nasdaq: VRTX) has been at odds with British regulators for several years over the 123,000 euro annual price tag (roughly $135,000 in U.S. dollars) it wants to charge for one of…

Boston Biz Journal https://www.bizjournals.com/boston/news/2019/09/12/vertex-strikes-deal-to-sell-cystic-fibrosis-drugs.html?ana=RSS&s=article_search